Double Whammy For Merck And Eisai’s Keytruda/Lenvima Combo In Solid Tumors
As LEAP Program Flounders
Executive Summary
The partners’ combination of Keytruda and Lenvima has missed the mark in two pivotal trials in melanoma and colorectal cancer, leading to one trial discontinuation and dashing hopes for important label expansions.
You may also be interested in...
Two LEAPs Behind: Merck/Eisai Post Pair Of Failures Of Keytruda/Lenvima Combo
The announcement that LEAP-006 and LEAP-008, both in non-small cell lung cancer, did not meet their primary endpoints adds to a string of failures for the combination.
Merck’s Keytruda And Seagen’s Padcev Become First PD-1/ADC Combo To Win US Approval
The blockbuster PD-1 inhibitor and antibody-drug conjugate will be used to treat a subset of first-line urothelial carcinoma patients considerably widening Padcev’s market, but rates of peripheral neuropathy with the combination have left some analysts concerned.
ESMO: Pivotal Keytruda Combination Hits And Misses
Merck & Co’s mega-blockbuster checkpoint inhibitor Keytruda hit new clinical highs and lows at ESMO as the major ramps up efforts to expand the drug’s label by exploring novel combinations and cancer settings.